A targeted staff education initiative and a simple visual cue significantly improved clinical awareness of peripheral nerve block complications, specifically fall or injury risks. The study authors...
A targeted staff education initiative and a simple visual cue significantly improved clinical awareness of peripheral nerve block complications, specifically fall or injury risks. The study authors...
A targeted staff education initiative and a simple visual cue significantly improved clinical awareness of peripheral nerve block complications, specifically fall or injury risks. The study authors...
A targeted staff education initiative and a simple visual cue significantly improved clinical awareness of peripheral nerve block complications, specifically fall or injury risks. The study authors...
A randomized phase 3 trial evaluated cebranopadol, a dual-NMR agonist, for postoperative pain after abdominoplasty and found reduced pain and opioid use. This study was presented on May 1, 2025, at the ASRA...
A randomized phase 3 trial evaluated cebranopadol, a dual-NMR agonist, for postoperative pain after abdominoplasty and found reduced pain and opioid use. This study was presented on May 1, 2025, at the ASRA...
A randomized phase 3 trial evaluated cebranopadol, a dual-NMR agonist, for postoperative pain after abdominoplasty and found reduced pain and opioid use. This study was presented on May 1, 2025, at the ASRA...
A randomized phase 3 trial evaluated cebranopadol, a dual-NMR agonist, for postoperative pain after abdominoplasty and found reduced pain and opioid use. This study was presented on May 1, 2025, at the ASRA...
A randomized phase 3 trial evaluated cebranopadol, a dual-NMR agonist, for postoperative pain after abdominoplasty and found reduced pain and opioid use. This study was presented on May 1, 2025, at the ASRA...
A randomized phase 3 trial evaluated cebranopadol, a dual-NMR agonist, for postoperative pain after abdominoplasty and found reduced pain and opioid use. This study was presented on May 1, 2025, at the ASRA...
